A pharmacy is valued on what it earns and on the contract that lets it earn. Both parts matter, and lenders look hard at each.
The basic mechanism
Community pharmacies are generally valued on a multiple of EBITDA (earnings before interest, tax, depreciation and amortisation), together with the value of the NHS or Health and Social Care contract income.
EBITDA is used rather than net profit because it strips out how the current owner has financed and structured the business, which tells you nothing about what the branch will earn under new ownership. The adjustments matter: an owner’s drawings, a family member on the payroll, or a rent paid to a connected party all need normalising before the multiple means anything.
The contract is what makes it lendable
This is the part that separates pharmacy from ordinary retail. The contract provides a base of predictable, government-backed income, and that predictability is what lenders are really buying into.
It also cuts the other way. Contractual frameworks change, and lenders watch those changes closely. A proposal that does not address contract stability directly will struggle however good the EBITDA looks.
Community pharmacy is contracted differently in England, Scotland, Wales and Northern Ireland. A valuation approach built around one framework does not transfer cleanly to another, which is worth knowing if you are buying outside the nation you already operate in.
What moves a branch up the range
- Growing prescription volumes with a demonstrable trend, not just an annual figure
- A healthy services income alongside dispensing, which diversifies the contract exposure
- A strong local position, particularly proximity to a GP surgery with an established referral pattern
- Freehold premises, or a long lease on sensible terms
- Efficient operation: automation, sensible staffing ratios
- Clean regulatory standing
What pulls it down
- Declining prescription volumes, or volumes propped up by a single care home contract
- Heavy dependence on dispensing with little services income
- A short unexpired lease, which is a genuine obstacle rather than a discount point
- A new competitor opening nearby, or a GP surgery relocating
- Deferred investment: ageing systems, a shopfit at the end of its life
- Concentration on a small number of prescribers
The care home question
A branch with a substantial care home dispensing contract can look highly profitable. Ask how long that contract runs, whether it has been tendered recently, and what the branch looks like without it.
Lenders will ask, and a valuation resting on a contract that could move next year is a valuation worth challenging. It is not a reason to walk away. It is a reason to price and structure differently.
Freehold, leasehold and the lease term
Where the freehold is included it is valued and funded separately from the business, on different terms. See pharmacy commercial mortgages.
On a leasehold branch, the unexpired term is the first thing to check. Lenders want the lease to comfortably exceed the loan term. If it does not, negotiating an extension with the landlord before you apply is far easier than doing it once terms are agreed and the clock is running.
Practical advice before you offer
- Get monthly prescription volumes, not annual, because the trend tells you more than the total
- Normalise the EBITDA properly, including any connected-party costs
- Establish the services versus dispensing split and how it has moved
- Check the lease term first on any leasehold branch
- Ask about any single contract representing a material share of volume
- Understand the contract framework for the nation the branch operates in
See also: pharmacy acquisition finance and group and portfolio finance.
All figures are indicative and subject to lender assessment, your circumstances, valuation and prevailing market conditions. Commercial mortgages and unregulated bridging loans are not regulated by the Financial Conduct Authority. Property offered as security may be at risk if you do not keep up repayments.